BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 04, 2008
 |  BioCentury  |  Product Development

Biophysics for targeting tissues

Surface Logix Inc. was founded on the belief that drugs could be designed to target specific physiological microenvironments, such as cell membranes of different tissues. Last week's results in a Phase IIa trial of SLx-4090 to treat dyslipidemia without liver toxicity gave the approach some credence.

SLx-4090 inhibits microsomal triglyceride transfer protein (MTP), which is involved in triglyceride absorption in enterocytes - the absorptive epithelial cells found in the small intestines and colon.

MTP inhibitors have been studied by numerous companies, but there has been a recurring problem of fatty liver, according to Leland Webster, VP of corporate development. "Over time, that can lead to cirrhosis and kill you," he added.

"The traditional pharmaceutical approach is to blast a compound...

Read the full 591 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >